Loading…
Loading…
FAMDF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for FAMDF and 80,000+ other tickers.
See exactly how FAMDF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for FAMDF and 80,000+ other tickers.
Futura Medical plc is a pharmaceutical company that formulates and brings to market healthcare solutions and medicines for the consumer sector, primarily concentrating on sexual well-being and managing discomfort. Their flagship product, MED3000, is a topical gel specifically developed to address erectile dysfunction. The company's pipeline also encompasses a range of pain relief treatments, featuring TPR100, a topical diclofenac gel; CBD100, a topical cannabidiol preparation; and TIB200, a topical ibuprofen gel. Established in 2001, Futura Medical plc operates from its headquarters located in Guildford, United Kingdom.
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) said its stronger Eroxon Intense erectile dysfunction gel has been cleared for launch across the European...
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) said its stronger Eroxon Intense erectile dysfunction gel has been cleared for launch across the European Economic Area and UK, widening the group's flagship consumer-health franchise. The clearance follows the completion of design, validation and pre-market regulatory work under Futura's existing European CE certification and UKCA approval.
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) chief executive Alex Duggan talked with Proactive about the company's new US commercial partnership for...
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) chief executive Alex Duggan talked with Proactive about the company's new US commercial partnership for Eroxon and encouraging new clinical data for its women's sexual health product candidate, WSD4000. Duggan explained why Futura Medical selected Market Performance Group (MPG) as its new US commercial partner, highlighting the group's extensive experience in consumer healthcare and its role in managing commercial execution, advertising, distribution and customer operations.
Exxon Mobil Corp (NYSE:XOM, XETRA:XONA) updated its second quarter 2026 earnings considerations after the market close on Tuesday, prompting UBS to slightly...